What is CelerisTx?
Founded in 2020, CelerisTx operates at the vanguard of the biopharmaceutical sector, utilizing its Celeris One platform to revolutionize the development of novel degrader molecules. The company's closed-loop discovery engine is designed to predict complex biomolecular interactions, effectively streamlining the path from initial chemical entity generation to biochemical validation. By focusing on high-impact therapeutic areas such as oncology and neurodegenerative diseases, CelerisTx addresses some of the most persistent challenges in modern medicine. Its business model, which combines internal pipeline development with strategic partnerships across the pharma and biotech landscape, allows for a diversified approach to drug discovery that maximizes both scientific output and commercial potential.
How much funding has CelerisTx raised?
CelerisTx has raised a total of $26.4M across 2 funding rounds:
Angel/Seed
$4.4M
Series A
$22M
Angel/Seed (2022): $4.4M with participation from i&i Biotech Fund, Apex Ventures, Pace Ventures Enigma, R42 Group, and Longevitytech.Fund
Series A (2022): $22M led by EIC Accelerator
Key Investors in CelerisTx
EIC Accelerator
BLDG Dotacje sp. z o.o. specializes in economic consulting and securing EU grants, supporting enterprises in R&D projects from concept design to project settlement.
R42 Group
R42 Group is a venture capital fund and institute focusing on deep science, AI, and biotech, supporting ventures from the pre-seed stage through to growth.
Longevitytech.Fund
LongevityTech.fund focuses on global investments in technologies designed to extend healthy lifespans and improve health outcomes through advanced innovation.
What's next for CelerisTx?
With the recent influx of capital, CelerisTx is poised to scale its R&D operations and deepen its integration within the global pharmaceutical ecosystem. The strategic focus will likely center on enhancing the predictive accuracy of the Celeris One platform and accelerating the transition of lead candidates into clinical development. As the company continues to refine its proprietary technology, it is expected to seek further collaborative ventures with established industry leaders to validate its degrader molecules in diverse therapeutic contexts. The ongoing commitment from its investor base suggests a long-term strategy aimed at establishing CelerisTx as a foundational provider of AI-driven drug design solutions, ultimately aiming to improve patient outcomes through precision medicine and accelerated research cycles.
See full CelerisTx company page
